Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Lytix Biopharma AS (LYTIX.OL)
Oslo, NO
Based in Oslo, Norway, Lytix Biopharma ASA is a clinical-stage biotechnology firm dedicated to advancing innovative immunotherapies for cancer treatment. Its primary drug candidate, LTX-315, is an oncolytic molecule currently undergoing Phase II clinical trials. This therapy is formulated for intratumoral injection, aiming to provide localized treatment for solid tumors. Additionally, Lytix Biopharma is developing LTX-401, another oncolytic molecule in its preclinical phase, specifically designed to target deep-seated cancerous lesions, including those found in liver cancer. The company was established in 2003.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -5.88% | -1.42% | +0.00% | +11.83% | +0.00% | +4.21% | +26.83% | +4.52% | -44.09% | -44.09% | -44.09% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%-100.0%
-
EPS growth Biotechnology: +29.7%+49.4% ★ Q1'26: -78.9% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%— Q1'26: +2,895.3% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+26.6% Q1'26: +12.7% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.05× Q1'26: -0.02× (vs Q1'25)
| Metric |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 2 Rev. Ana. 1 EPS Ana. |
Dec 2027 2 Rev. Ana. 1 EPS Ana. |
Dec 2028 2 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|
| Revenue |
11.13M
est: 6.30M (+76.7%)
|
—
est: 1.70M (-100.0%)
|
32.95M
24.90M – 41.00M
+1,838.2% YoY
|
77.65M
58.68M – 96.62M
+135.7% YoY
|
35.35M
26.71M – 43.99M
-54.5% YoY
|
| EBITDA |
-93.22M
est: -3.78M (-2,366.2%)
|
-63.02M
est: -1.02M (-6,078.8%)
|
-19.77M
-24.60M – -14.94M
-1,838.2% YoY
|
-46.59M
-57.97M – -35.21M
-135.7% YoY
|
-21.21M
-26.39M – -16.03M
+54.5% YoY
|
| EBIT |
-94.14M
est: -3.78M (-2,390.4%)
|
-64.03M
est: -1.02M (-6,177.3%)
|
-19.77M
-24.60M – -14.94M
-1,838.2% YoY
|
-46.59M
-57.97M – -35.21M
-135.7% YoY
|
-21.21M
-26.39M – -16.03M
+54.5% YoY
|
| Net Income |
-94.27M
|
-59.98M
est: -73.00M (+17.8%)
|
-50.00M
-62.31M – -32.27M
+31.5% YoY
|
-105.00M
-123.71M – -64.07M
-110.0% YoY
|
-110.00M
-129.13M – -66.88M
-4.8% YoY
|
| SGA |
—
est: 1.26M (-100.0%)
|
49.23M
est: 340.0K (+14,378.3%)
|
6.59M
4.98M – 8.20M
+1,838.2% YoY
|
15.53M
11.74M – 19.32M
+135.7% YoY
|
7.07M
5.34M – 8.80M
-54.5% YoY
|
| EPS |
-1.74
|
-0.88
est: -1.07 (+17.7%)
|
-0.69
-0.91 – -0.47
+35.5% YoY
|
-1.37
-1.81 – -0.93
-98.6% YoY
|
-1.43
-1.88 – -0.98
-4.4% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-26 | C | 2/5 | 2/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-22 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-21 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-20 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-19 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-18 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-15 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-13 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-12 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-11 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-08 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-07 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-06 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-05 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-04 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-30 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-29 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-28 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-27 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-24 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-23 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-22 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-21 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-20 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-17 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-16 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Oystein Rekdal | Co-Founder & Chief Executive Officer | 5M | — |
| Baldur Sveinbjørnsson | Chief Scientific Officer | — | — |
| Brent Meadows | CBO | — | male |
| Gjest Breistein | Chief Financial Officer | — | male |
| Jacqueline Earabino | Head of Clinical Operations | — | — |
| Mette Husbyn | Chief Technology Officer | — | — |
| Ole Peter Nordby | Head of IR & Communication Manager | — | male |
| Ahmed Bouzidi | Senior Vice President of Business Development | — | — |
| Renee Christine Amundsen | Chief Operating Officer | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for LYTIX.OL
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
